Different profile of cytokine production in patients with systemic sclerosis and association with clinical manifestations

Dantas, Andréa Tavares; Almeida, Anderson Rodrigues de; Sampaio, Maria Clara Pinheiro Duarte; Cordeiro, Marina Ferraz; Oliveira, Priscilla Stela Santana de; Mariz, Henrique de Ataíde; Pereira, Michelly Cristiny; Rêgo, Moacyr Jesus Barreto de Melo; Pitta, Ivan da Rocha; Duarte, Ângela Luzia Branco Pinto; Pitta, Maíra Galdino da Rocha

doi:10.1016/j.imlet.2018.03.011

Cited by 28 publications

(27 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chronic pain can independently contribute to the pathogenesis of depression, through elevation of inflammatory cytokines IL‐1β, IL‐6, and TNF‐α . Here, we review the prevalence and characteristics of depression, and its correlation to the levels of inflammatory cytokines and disease activity among different CTD (Tables and ).…”

Section: Depression In Connective Tissue Diseasesmentioning

confidence: 99%

“…Immune dysregulation and production of inflammatory cytokines is central to the pathogenesis of SSc. The substantial difference in cytokine profile observed in SSc patients compared to healthy controls is associated with clinical manifestations during the course of the disease . Elevated production levels of IL‐6, IL‐1, TNF‐α, IFN‐γ, IL‐10, and IL‐2 were observed in serum samples of patients .…”

Section: Depression In Connective Tissue Diseasesmentioning

confidence: 99%

“…The substantial difference in cytokine profile observed in SSc patients compared to healthy controls is associated with clinical manifestations during the course of the disease . Elevated production levels of IL‐6, IL‐1, TNF‐α, IFN‐γ, IL‐10, and IL‐2 were observed in serum samples of patients . IL‐6, IL‐2, and IL‐10, in particular, have been found to strongly reflect the extent of disease activity and internal organ involvement …”

Section: Depression In Connective Tissue Diseasesmentioning

confidence: 99%

“…Elevated production levels of IL‐6, IL‐1, TNF‐α, IFN‐γ, IL‐10, and IL‐2 were observed in serum samples of patients . IL‐6, IL‐2, and IL‐10, in particular, have been found to strongly reflect the extent of disease activity and internal organ involvement …”

Section: Depression In Connective Tissue Diseasesmentioning

confidence: 99%

See 3 more Smart Citations

Cytokine secretion and the risk of depression development in patients with connective tissue diseases

Grygiel-Górniak

Limphaibool

Puszczewicz

2019

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Research in the past two decades has revolutionized our understanding of depressive illnesses. Proinflammatory cytokines have become a point of interest in the interconnecting areas of neuropsychiatric and autoimmune diseases. The cytokine hypothesis of depression suggests that pro‐inflammatory cytokines play a primary role in the mediation of the pathophysiological characteristics of major depression, in which an inflammatory process may be induced by external and internal stressors, such as psychological and inflammatory diseases, respectively. The higher prevalence of depression, particularly in patients with chronic autoimmune connective tissue disorders (CTD), suggests that depression may present a dysfunctional adaptation of cytokine‐induced sickness, which could manifest in times of an exacerbated activation of the innate immune system. Inflammation is thought to contribute to the development of clinical depression through its ability to induce sickness behaviors corresponding to the neurovegetative features of depression, through the dysregulation of the hypothalamic–pituitary–adrenal axis, alterations in neurotransmitter synthesis and reuptake, and through its involvement in the neuroprogression pathways. This review explores the complex interrelationships in which inflammatory responses alter neuroendocrine and neuropsychological regulation contributing to depressive symptoms in CTD. The prevalence and characteristics of depression, and its correlation to the levels of inflammatory cytokines and disease activity among different CTD will be reviewed.

show abstract

Section: Depression In Connective Tissue Diseasesmentioning

confidence: 99%

Section: Depression In Connective Tissue Diseasesmentioning

confidence: 99%

Section: Depression In Connective Tissue Diseasesmentioning

confidence: 99%

Section: Depression In Connective Tissue Diseasesmentioning

confidence: 99%

See 2 more Smart Citations

Cytokine secretion and the risk of depression development in patients with connective tissue diseases

Grygiel-Górniak

Limphaibool

Puszczewicz

2019

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

show abstract

“…The complex role of the immune system in the pathogenesis of SSc is further highlighted by the detection of substantial differences in cytokine production in SSc, with differences according to cutaneous and internal organ involvement ( 59 , 60 ).…”

Section: Immune Cells and Vascular Leaking In Sscmentioning

confidence: 99%

Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?

et al. 2018

View full text Add to dashboard Cite

The early phase of systemic sclerosis (SSc) presents edema as one of the main features: this is clinically evident in the digital swelling (puffy fingers) as well as in the edematous skin infiltration of the early active diffuse subset. Other organs could be affected by this same disease process, such as the lung (with the appearance of ground glass opacities) and the heart (with edematous changes on cardiac magnetic resonance imaging). The genesis of tissue edema is tightly linked to pathological changes in the endothelium: various reports demonstrated the effect of transforming growth factor β, vascular endothelial growth factor and hypoxia-reperfusion damage with reactive oxygen species generation in altering vascular permeability and extravasation, in particular in SSc. This condition has an alteration in the glycocalyx thickness, reducing the protection of the vessel wall and causing non-fibrotic interstitial edema, a marker of vascular leak. Moreover, changes in the junctional adhesion molecule family and other adhesion molecules, such as ICAM and VCAM, are associated with an increased myeloid cells' extravasation in the skin and increased myofibroblasts transformation with further vascular leak and cellular migration. This mini-review examines current knowledge on determinants of vascular leak in SSc, shedding light on the role of vascular protection. This could enhance further studies in the light of drug development for early treatment, suggesting that the control of vascular leakage should be considered in the same way that vasodilation and inflammation reduction, as potential therapeutic targets.

show abstract

Engineering Advanced In Vitro Models of Systemic Sclerosis for Drug Discovery and Development

et al. 2021

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a complex multisystem disease with the highest case‐specific mortality among all autoimmune rheumatic diseases, yet without any available curative therapy. Therefore, the development of novel therapeutic antifibrotic strategies that effectively decrease skin and organ fibrosis is needed. Existing animal models are cost‐intensive, laborious and do not recapitulate the full spectrum of the disease and thus commonly fail to predict human efficacy. Advanced in vitro models, which closely mimic critical aspects of the pathology, have emerged as valuable platforms to investigate novel pharmaceutical therapies for the treatment of SSc. This review focuses on recent advancements in the development of SSc in vitro models, sheds light onto biological (e.g., growth factors, cytokines, coculture systems), biochemical (e.g., hypoxia, reactive oxygen species) and biophysical (e.g., stiffness, topography, dimensionality) cues that have been utilized for the in vitro recapitulation of the SSc microenvironment, and highlights future perspectives for effective drug discovery and validation.

show abstract

Different profile of cytokine production in patients with systemic sclerosis and association with clinical manifestations

Cited by 28 publications

References 31 publications

Cytokine secretion and the risk of depression development in patients with connective tissue diseases

Cytokine secretion and the risk of depression development in patients with connective tissue diseases

Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?

Engineering Advanced In Vitro Models of Systemic Sclerosis for Drug Discovery and Development

Contact Info

Product

Resources

About